Interneuron metabolic news

IPIC submitted a letter of understanding to the U.S. District Court for the Eastern District of Pennsylvania proposing a settlement of suits filed by users of the company's Redux dexfenfluramine for obesity. IPIC and marketing partner Wyeth-Ayerst Laboratories (Radnor, Penn.) withdrew Redux from the U.S. last year after concerns surfaced over possible heart valve defects associated with use of the drug (see BioCentury Extra, Sept. 16, 1997).

The deal reached with plaintiffs in suits currently filed against the company is contingent on the court's certification that future claims against IPIC would be paid out of a settlement fund established by the agreement, although claimants would still be free to make claims against Wyeth-Ayerst. ...